Our scientific team will provide comprehensive information tailored to your laboratory research objectives.
Advanced Metabolic Peptide
Tesamorelin 6mg + Ipamorelin 3mg + CJC-1295 3mg
- Supports investigation of multi-pathway GH axis modulation
- Enables analysis of pulsatile endocrine signaling patterns
- Assists in studying receptor synergy and signaling amplification mechanisms
- Contributes to IGF-1 pathway and somatotropic axis research frameworks
- Facilitates deeper understanding of coordinated neuroendocrine interactions
Product Overview
Tesamorelin (a growth hormone–releasing hormone analogue), Ipamorelin (a selective growth hormone secretagogue), and CJC-1295 (a GHRH analogue) are combined in this triple-peptide formulation to investigate coordinated modulation of the somatotropic axis within controlled laboratory environments.
In experimental research models, Tesamorelin and CJC-1295 are studied for their interaction with GHRH receptors, contributing to upstream signaling of growth hormone release, while Ipamorelin is examined for its selective activation of GHS-R1a receptors. This multi-pathway engagement allows researchers to explore pulsatile GH secretion dynamics, receptor-specific signaling interactions, and downstream IGF-1 pathway modulation.
The combination is particularly relevant in structured endocrine studies evaluating synergistic receptor activation, temporal signaling patterns, and integrated neuroendocrine feedback systems under controlled experimental conditions.
At Nexzya Bioscience, this triple-peptide complex is produced under stringent research-grade standards. Each batch undergoes advanced analytical validation to confirm molecular identity, structural precision, and purity compliance. Our quality assurance systems ensure reproducibility, traceability, and consistency for high-level endocrine and metabolic research applications.
Key Characteristics
- Triple-peptide formulation combining Tesamorelin, Ipamorelin, and CJC-1295
- Dual GHRH analogue activity (Tesamorelin + CJC-1295) for upstream signaling research
- Selective GHS-R1a receptor activation via Ipamorelin
- Designed for coordinated somatotropic axis investigation
- High-purity research-grade peptide formulation
- Molecular identity verified through advanced analytical testing
- Studied in pulsatile growth hormone release models
- Examined for receptor-specific and multi-pathway signaling dynamics
- Stable under recommended laboratory storage conditions
- Batch-specific analytical documentation and traceability available
Direct Research Applications & Potential Benefits
- Supports investigation of multi-pathway GH axis modulation
- Enables analysis of pulsatile endocrine signaling patterns
- Assists in studying receptor synergy and signaling amplification mechanisms
- Contributes to IGF-1 pathway and somatotropic axis research frameworks
- Facilitates deeper understanding of coordinated neuroendocrine interactions
Final Overview
Tesamorelin 6mg + Ipamorelin 3mg + CJC-1295 3mg from Nexzya Bioscience reflects our commitment to advanced peptide engineering, analytical precision, and scientific rigor. Developed exclusively for controlled laboratory investigation, this triple-modulation complex adheres to strict research-grade standards to ensure reliable and reproducible performance across advanced endocrine research models.
For laboratories requiring analytically verified multi-peptide systems for structured growth hormone axis exploration, Nexzya Bioscience delivers research-grade solutions grounded in methodological excellence and quality assurance.
Request Technical Information
To receive detailed analytical reports, batch specifications, and technical documentation for Tesamorelin 6mg + Ipamorelin 3mg + CJC-1295 3mg, please complete the form below with your name and email.
Advanced Peptide Science & Biomolecular Research
South Korea — 대한민국
Czech Republic — Česká republika
Resources
NEXZYA™ Bioscience | Since 1986 All Rights Reserved